Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lauren Van Lancker

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
European Journal of Ophthalmology|October 15, 2016
Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularizationLauren Van Lancker, Robert Petrarca, Kyros Moutsouris, et al.
Ophthalmology. Glaucoma|June 11, 2023
ReplySancy Low, Lauren Van Lancker, Caroline Barwood, et al.
Ophthalmology. Glaucoma|November 25, 2022
Clinical Outcomes and Cost Analysis of PreserFlo versus Trabeculectomy for Glaucoma Management in the United KingdomLauren Van Lancker, Amrita Saravanan, Mohammed Abu-Bakra, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
European Journal of Ophthalmology|October 15, 2016
Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularizationLauren Van Lancker, Robert Petrarca, Kyros Moutsouris, et al.
Ophthalmology. Glaucoma|June 11, 2023
ReplySancy Low, Lauren Van Lancker, Caroline Barwood, et al.
Ophthalmology. Glaucoma|November 25, 2022
Clinical Outcomes and Cost Analysis of PreserFlo versus Trabeculectomy for Glaucoma Management in the United KingdomLauren Van Lancker, Amrita Saravanan, Mohammed Abu-Bakra, et al.
Pageof 1